Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AUNANASDAQ:CSTLNASDAQ:FLGTNASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUNAAuna$6.20-2.2%$6.66$6.11▼$9.38$469.24M2.553,404 shs338,511 shsCSTLCastle Biosciences$20.42+0.3%$18.07$15.45▼$35.84$587.55M1.04425,244 shs527,611 shsFLGTFulgent Genetics$19.88+1.0%$20.00$14.57▼$25.11$599.13M1.06285,577 shs195,019 shsTOIOncology Institute$2.05-6.4%$2.73$0.13▼$3.50$195.42M0.131.10 million shs1.27 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUNAAuna0.00%+2.01%-1.55%-10.83%-20.75%CSTLCastle Biosciences0.00%+9.88%+27.43%+1.65%-6.52%FLGTFulgent Genetics0.00%+0.77%-4.51%+16.45%+0.31%TOIOncology Institute0.00%-8.37%-31.78%+92.11%+376.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUNAAuna3.5632 of 5 stars3.22.00.00.02.00.03.1CSTLCastle Biosciences2.6661 of 5 stars3.54.00.00.01.62.50.0FLGTFulgent Genetics3.4032 of 5 stars2.31.00.04.12.03.30.6TOIOncology Institute1.8016 of 5 stars3.52.00.00.02.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUNAAuna 2.33Hold$10.7072.58% UpsideCSTLCastle Biosciences 3.00Buy$37.0081.19% UpsideFLGTFulgent Genetics 2.50Moderate Buy$24.0020.72% UpsideTOIOncology Institute 3.00Buy$7.00241.46% UpsideCurrent Analyst Ratings BreakdownLatest TOI, CSTL, FLGT, and AUNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025AUNAAunaHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/22/2025AUNAAunaHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$7.905/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/15/2025TOIOncology InstituteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.005/5/2025FLGTFulgent GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUNAAuna$1.17B0.39$1.14 per share5.42$5.85 per share1.06CSTLCastle Biosciences$332.07M1.78$0.99 per share20.68$16.28 per share1.25FLGTFulgent Genetics$283.47M2.13N/AN/A$36.92 per share0.54TOIOncology Institute$393.41M0.46N/AN/A$0.05 per share41.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUNAAuna$29.39M$0.5810.697.85N/A3.67%10.39%2.38%8/20/2025 (Estimated)CSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)FLGTFulgent Genetics-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)TOIOncology Institute-$64.66M-$0.70N/A∞N/A-15.38%-445.02%-34.13%8/12/2025 (Estimated)Latest TOI, CSTL, FLGT, and AUNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025AUNAAuna$0.16$0.19+$0.03$0.13$1.12 billion$281.43 million5/14/2025Q1 2025TOIOncology InstituteN/A-$0.18N/A-$0.21N/A$104.41 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUNAAunaN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUNAAuna1.760.830.78CSTLCastle Biosciences0.029.379.19FLGTFulgent GeneticsN/A6.326.32TOIOncology Institute14.581.791.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUNAAunaN/ACSTLCastle Biosciences92.60%FLGTFulgent Genetics48.06%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipAUNAAunaN/ACSTLCastle Biosciences7.20%FLGTFulgent Genetics33.11%TOIOncology Institute8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUNAAuna14,84274.01 millionN/AN/ACSTLCastle Biosciences54028.87 million26.79 millionOptionableFLGTFulgent Genetics1,31330.44 million20.36 millionOptionableTOIOncology Institute66089.23 million81.65 millionNot OptionableTOI, CSTL, FLGT, and AUNA HeadlinesRecent News About These CompaniesThe Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in NevadaJune 30 at 4:05 PM | globenewswire.comInvesting in Oncology Institute (NASDAQ:TOI) a year ago would have delivered you a 376% gainJune 29 at 6:12 PM | finance.yahoo.comOncology Institute (NASDAQ:TOI) versus NeueHealth (NYSE:NEUE) Head to Head AnalysisJune 27 at 2:26 AM | americanbankingnews.comA game-changer in cancer research? South Korean scientists reprogram tumour cells without chemotherapy or radiationJune 25, 2025 | msn.comTOI - The Oncology Institute Inc Sustainability - MorningstarJune 24, 2025 | morningstar.comMApprovals for oncology procedures rise under Ayushman Bharat Arogya Karnataka schemeJune 10, 2025 | timesofindia.indiatimes.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 10, 2025 | insidertrades.comJane Street Group LLC Has $39,000 Holdings in The Oncology Institute, Inc. (NASDAQ:TOI)June 10, 2025 | marketbeat.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 673,676 Shares of StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 1,976,137 Shares of StockJune 6, 2025 | insidertrades.comBrad Hively Sells 1,976,137 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) StockJune 5, 2025 | marketbeat.comThe Oncology Institute set to join the Russell 2000® and Russell 3000® IndexesJune 3, 2025 | globenewswire.comShort Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 26.4%June 3, 2025 | marketbeat.comOncology Institute (NASDAQ:TOI) Trading Up 2.9% - Time to Buy?May 31, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 203,532 Shares of StockMay 23, 2025 | insidertrades.comOncology Institute First Quarter 2025 Earnings: US$0.25 loss per share (vs US$0.22 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comOncology Institute Shares Rise After Higher 1Q RevenueMay 15, 2025 | marketwatch.comThe Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 GuidanceMay 15, 2025 | finanznachrichten.deTOI reaffirms 2025 guidance with $460M–$480M revenue target as capitation contracts fuel growthMay 15, 2025 | msn.comQ1 2025 Oncology Institute Inc Earnings CallMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOI, CSTL, FLGT, and AUNA Company DescriptionsAuna NYSE:AUNA$6.20 -0.14 (-2.21%) As of 03:58 PM EasternAuna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.Castle Biosciences NASDAQ:CSTL$20.42 +0.07 (+0.34%) As of 04:00 PM EasternCastle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Fulgent Genetics NASDAQ:FLGT$19.88 +0.20 (+1.02%) As of 04:00 PM EasternFulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Oncology Institute NASDAQ:TOI$2.05 -0.14 (-6.39%) As of 04:00 PM EasternThe Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
